Like A Healthy Dose on Facebook  Tweet about A Healthy Dose





World Malaria Day 2015

Collage of images: people holding signs with messages of support for the fight against malaria, crowd at reception hosted by PATH.

On April 24, 2015, the Bay Area World Malaria Day Symposium, co-sponsored by PATH, University of California, Davis, and Zagaya, was held on the Clark Kerr campus at University of California, Berkeley. The day was composed of three main sessions: research and exploration; implementation of campaigns, programs, and policies; and technical innovation. Keynote speakers included Ashley Birkett, director of PATH’s Malaria Vaccine Initiative, and Dr. Patrick E. Duffy, chief of the laboratory of malaria immunology and vaccinology at the National Institute of Allergy and Infectious Diseases, National Institutes of Health. Following the symposium, PATH hosted an informal networking reception on the Clark Kerr campus.




Enrollment underway for HIV PrEP
phase 2 trial

All four clinical sites—New Jersey and New York in the United States, Cape Town in South Africa, and Harare in Zimbabwe—are now active and recruiting participants, with 37 women enrolled as of June 22. The trial—HPTN 076—will compare the safety and acceptability of intramuscular injections of rilpivirine (TMC 278) long-acting to placebo injections given once every eight weeks over a 10-month period among sexually active, HIV-uninfected women. For more information about HPTN 076, see using the identifier NCT02165202.


Improving treatments in pneumonia

In collaboration with Save the Children, University of Washington, Malawi Ministry of Health, and Malawi College of Medicine, we are working to build the evidence base for appropriate and effective treatment of childhood pneumonia in Africa. Later this year, following completion of the ethical approval process, we will be launching two double-blinded, randomized, non-inferiority clinical trials to compare the effectiveness of placebo versus three days of treatment with amoxicillin dispersible tablets (DT) for fast-breathing pneumonia, and three versus five days amoxicillin DT for chest-indrawing pneumonia among children 2 to 59 months of age.


Millions of malaria drugs made with ssART shipped

A few months ago, we announced that the first batches of malaria drugs (Sanofi’s Artesunate Amodiaquine Winthrop® or ASAQ) made with artesunate derived from new semisynthetic artemisinin (ssART) began reaching endemic countries in Africa. Since then, approximately 16 million ASAQ treatments made using semisynthetic material have been shipped to 17 countries across sub-Saharan Africa. Sustained production of ssART and its smart integration into the market paves the way for artemisinin to be readily available for development and deployment of lifesaving malaria treatments.




#DefeatMalaria campaign

Leading up to World Malaria Day in April, our team joined the #DefeatMalaria global campaign led by Roll Back Malaria. Through a coordinated social media campaign and blog series, individuals and organizations, including Medicines for Malaria Venture, Malaria No More, and PATH, commemorated historic strides worldwide, calling for sustained investment to further accelerate progress toward elimination. Catch up on the blog series on the Roll Back Malaria website and read “The end of malaria is within reach” by Dr. Kent Campbell, director of PATH’s newly formed Malaria Center of Excellence.


#Blue4Water on World Water Day

Drug Development staff wearing blue in support of #Blue4Water event.

On World Water Day, March 20, 2015, our team went #Blue4Water to raise awareness about the critical need for safe drinking water and sanitation for global health and to celebrate the recent victory of the passage of the Water for the World Act. Check out more photos from the campaign by individuals, government agencies, and nonprofit organizations on Storify.




When I think of drug development...

Complex, rewarding, innovative, challenging—we asked our staff to pause and reflect on what drug development represents to them. Read more responses from our team and learn about the process of developing a new drug on our blog.




June 2015


Loud and Clear


Featured Photo


In the News


On Our Blog


Get Connected




All photos: PATH.



PATH - A catalyst for global health


PO Box 900922 |
Seattle, WA 98109 USA
2201 Westlake Avenue, Suite 200 |
Seattle, WA 98121 USA
Tel: 206.285.3500 | Fax: 206.285.6619 |


   Like News from PATH on Facebook


Tweet about News from PATH